AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00300274
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids standard dose.
Trial: NCT03372044
Drug: PF-06865571 Slow release MR tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified release tablets
Trial: NCT00148915
Drug: ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00148915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01170650
Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
RxNorm normalized name: doxorubicin hydrochloride liposome Injection [Caelyx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
Trial: NCT01170650
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
Trial: NCT01456117
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone matching placebo once daily for up to 14 days.
Trial: NCT04665947
Drug: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET imaging using \[68Ga\]Ga DOTA-5G will be used to diagnose patients who are eligible for treatment with the \[177Lu\]Lu DOTA-ABM-5G.
Trial: NCT00442910
Drug: 3% SPL7013 Gel (VivaGel)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% vaginal gel
Trial: NCT00442910
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for SPL7013 gel
Trial: NCT00442910
Drug: HEC Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC Placebo gel intravaginally bd for 14 days
Trial: NCT03862248
Drug: 6EH³RZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
Trial: NCT03862248
Drug: 6EHR³Z
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
Trial: NCT03862248
Drug: 6EHRZLfx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO levofloxacin-strengthened regimen (6EHRZLfx)
Trial: NCT05084456
Drug: ModraDoc006/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
Trial: NCT03239522
Drug: [14C]-GSK1278863 solution for IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
Trial: NCT03239522
Drug: [14C]-GSK1278863 oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
Trial: NCT02468739
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
Trial: NCT00929539
Drug: JTT-130 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT01423370
Drug: YHD1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5g oral once daily
Trial: NCT01423370
Drug: YHD1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5g oral twice a day
Trial: NCT01423370
Drug: YHD1023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g oral once daily
Trial: NCT01423370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00134459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02742441
Drug: 122-0551 Foam
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Foam containing active drug
Trial: NCT02709902
Drug: EPIDUO® FORTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel
Trial: NCT02468674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo~Patients enrolled prior to the protocol amendment 1 (Population I), who received placebo in core study, entered the extension study at Week 25 and received placebo as an intravenous infusion starting at Week 25 after treatment was initiated in the core study until week 45.
Trial: NCT03980041
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally in 28-day cycles
Trial: NCT02709902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel
Trial: NCT00583609
Drug: PEG3350
RxNorm normalized name: PEG3350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG3350
Trial: NCT00560235
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
Trial: NCT03991975
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT00732290
Drug: Clopidogrel then fluoxetine+clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
Trial: NCT02576600
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCI
Trial: NCT02939391
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT04218695
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50cc intravenous once daily
Trial: NCT00234741
Drug: STA-5326 mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00094172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet form
Trial: NCT00002734
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00008203
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01582165
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 20 mg once daily vs placebo for 6 months
Trial: NCT01582165
Drug: Placebo.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily vs rosuvastatin for 6 months
Trial: NCT00483899
Drug: GW870086X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
Trial: NCT00483899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GW870086X will be administered by subjects
Trial: NCT00004099
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004099
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01550588
Drug: Standard medical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical management using anti-coagulant therapy
Trial: NCT02468232
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The target dose during the study was LCZ696 200 mg bid given orally. LCZ696 was supplied as 50 mg, 100 mg and 200 mg film-coated tablets.
Trial: NCT02468232
Drug: Placebo to LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 Placebo 50 mg, 100 mg and 200 mg film-coated tablets
Trial: NCT04065308
Drug: Drug Combinations
RxNorm normalized name: Other anti-dementia drug combinations in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response \<CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~1. dexamethasone :40mg/day D1-4, intravenous~2. cyclophosphamide: 400mg/m2 D1-4, intravenous~3. etoposide: 40mg/m2 D1-4, intravenous~4. cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle
Trial: NCT02083315
Drug: TRV130 1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV130 1.5 mg IV x 1 dose
Trial: NCT02083315
Drug: TRV130 3 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV130 3 mg IV x 1 dose
Trial: NCT02083315
Drug: TRV130 4.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRV130 4.5 mg IV x 1 dose
Trial: NCT02083315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in water IV x 1 dose
Trial: NCT00355628
Drug: KW-2246 (fentanyl citrate)
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: KW-2246
Trial: NCT01421706
Drug: sibutramine-Clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sibutramine-Clarithromycin
Trial: NCT00758849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
Trial: NCT00995410
Drug: PA32540
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
Trial: NCT00146523
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00713323
Drug: Sativex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Trial: NCT03478280
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
Trial: NCT00818883
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment.
Trial: NCT02127853
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
Trial: NCT04149626
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sedation using remifentanil (initial bolus dose followed by continuous infusion)
Trial: NCT00437177
Drug: [(123)I] iodobenzamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[(123)I\] iodobenzamide 185 MBq I.V., at discharge.
Trial: NCT01458236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
Trial: NCT00818883
Drug: Azilsartan medoxomil and hydrochlorothiazide
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment.
Trial: NCT02840565
Drug: BIA 5-453
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
Trial: NCT02840565
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
Trial: NCT00939653
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
Trial: NCT04480398
Drug: Guduchi Ghan Vati
RxNorm normalized name: vatinoxan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guduchi Ghan Vati is an Ayuvedic classical preparation which is prepared from aqueous of extract of Tinospora cordifolia.
Trial: NCT01050855
Drug: RIC: Distal Campath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Trial: NCT01050855
Drug: RIC:Intermediate Campath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
Trial: NCT01582204
Drug: 124IcG250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pts will undergo baseline disease assessment with CT scans (chest, abd \& pelvis), 124I-cG250-PET/CT \& Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan \& 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, \& pelvis with contrast after cycles 2, 3, 4 \& 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline \& week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, \& serial blood sampling, following the lst inj of 124I-cG250.
Trial: NCT02010762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral drops
Trial: NCT00569062
Drug: GW856553X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW856553X 7.5mg BID for 6 weeks
Trial: NCT01485965
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg, immediate release tablets, once daily administration
Trial: NCT00944671
Drug: famotidine (+) calcium carbonate (+) magnesium hydroxide tablet
RxNorm normalized name: calcium carbonate / famotidine / magnesium hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
Trial: NCT00944671
Drug: Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
Trial: NCT01624376
Drug: DLX105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
Trial: NCT01624376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections are administered over the treatment period of 4 weeks.
Trial: NCT00944671
Drug: Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
Trial: NCT00775034
Drug: Tisseel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesh repair for open incisional hernia repair with fibrin sealant
Trial: NCT00674297
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluvastatin 40 mg daily for 3 months
Trial: NCT04919421
Drug: Dental injection and topical gel application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
Trial: NCT02678975
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Disulfiram 400 mg daily
Trial: NCT02678975
Drug: Alkylating Agents
RxNorm normalized name: ALKYLATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkylating antineoplastic agent
Trial: NCT00621530
Drug: ketorolac tromethamine opthalmic solution
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
Trial: NCT04286750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered as hard capsules for oral use.
Trial: NCT00621530
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be added to the patient's routine spinal anesthetic for surgery
Trial: NCT01255020
Drug: α-Keto Acid with restricted protein diet
RxNorm normalized name: Keto-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d
Trial: NCT01255020
Drug: Placebo plus restricted protein diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d.
Trial: NCT03414632
Drug: 99mTc-PYP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioisotope used in the SPECT/CT imaging
Trial: NCT00227448
Drug: intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03949530
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00699504
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo IV and oral
Trial: NCT05116228
Drug: 500mg RTX Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1x500mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
Trial: NCT05116228
Drug: 1000mg RTX Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 1x1000mg RTX (Mabthera) at baseline (time-point of their upcoming semi-annual infusion) and at months 6, 12, 18 and 24
Trial: NCT00977288
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, once daily for 8 weeks
Trial: NCT04462263
Drug: HTL0014242
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid suspension capsule
Trial: NCT00795574
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
Trial: NCT03825809
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03825809
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT03825809
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-Operative Non Opioid Pain Protocol
Trial: NCT00449150
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01146483
Drug: Rosuvastatin, Pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study.
Trial: NCT04139135
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
Trial: NCT02214472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no